1 BTC
=
- USD
Oric Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Oric Pharmaceuticals, Inc. Common Stock
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Market Statistics
Trading Metrics
How to Buy ORIC
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ORIC
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals following a 41% stock price decline on March 31, 2026. The drop occurred after the company announced that its prostate cancer treatment (rinzimetostat/ORIC-944) performed roughly as effectively as competitors, falling short of expectations that it would be the best-in-class PRC2 blocker.
ORIC Pharmaceuticals announced equity inducement grants of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee hired in March 2026. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and vest over time based on continued employment.
ORIC Pharmaceuticals (NASDAQ: ORIC) surged 3.94% during regular trading but plummeted 24.86% in after-hours trading despite releasing positive Phase 1b clinical data for its lead drug candidate rinzimetostat in combination with darolutamide for metastatic castration-resistant prostate cancer. The treatment showed an 84% radiographic progression-free survival rate with favorable safety outcomes, and the company selected a 400 mg once-daily dose for Phase 3 trials expected to begin in H1 2026. The sharp after-hours decline suggests investor caution around early-stage results or profit-taking.
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.